The aim of this study is to present evaluation of treatment toxicity and the rate of local control in non-small cell lung cancer patients (NSCLC) treated with stereotactic body radiotherapy (SBRT). The analysis was performed on heterogenous group of 61 NSCLC patients, treated with SBRT between 2005 and 2008. It included 26 patients in clinical stage I, 5 in stage II, 22 in III and 8 in stage IV. In 30 patients SBRT was the only treatment, in 20 patients SBRT was a salvage therapy and in 11 patients SBRT was used as a boost after conventionally fractionated radiotherapy (CRT). The mean age was 67 yrs. Fifteen patients received chemotherapy in the course of treatment. Radiation doses were converted into Linear Quadratic Equivalent Dose at 2Gy per fraction (LQED2). The survival curves were plotted using Kaplan-Maier estimator and analyzed using log-rank test and Cox method. The LQED2 doses administered in stereotactic technique ranged from 8 Gy to 150 Gy and the fraction doses from 5 Gy to 24 Gy. The rate of 2 years local control correlated with LQED2: it was 81% in a group of patients who received over 110 Gy, compared to 51% and 33% in a group of patients who received 60-110 Gy and less than 30 Gy respectively. Prior radiotherapy and advanced clinical stage correlated with lower doses at SBRT and hence lower rate of local control. The tolerance of SBRT was satisfactory: there was no RTOG grade 3 -4 toxicity. The results are consistent with findings of other authors and indicate that LQED2 doses delivered by SBRT in the treatment of NSCLC should be higher than 110 Gy whenever clinically feasible. SBRT used as a salvage therapy was less effective, because use of high doses was precluded due to consideration of normal tissue tolerance.
Surgery is commonly considered to be a treatment of choice in stage I lung cancer. It provides 5 years local control of about 90%, and a satisfactory 5 years overall survival [1, 2] . Radiotherapy, which is commonly considered for patients inoperable due to poor performance status or comorbidities carried, until recently, worse prognosis. Percentage of local failure after conventional radiotherapy in stage I non-small cell lung cancer (NSCLC) of lung cancer patients is about 30% and 5 years overall survival 50% or less [3, 4] . Although dose escalation trials using conventionally fractionated radiotherapy indicate that higher doses result in higher percentage of local control, even doses of over 100 Gy did not provide satisfactory local control and were associated with an unacceptable risk of complications [5, 6, 7] . This phenomenon has been called a "plateau effect" and might be related to repopulation of clonogenic tumor cells between fractions of radiotherapy [8] . Over the last years many investigators showed, however, that higher percentage of local control can be achieved with SBRT -Stereotactic Body Radiotherapy [9, 10] . The fundamental concept of SBRT is to deliver few high dose fractions within short period of time to small target volume constrained to a tumor with a minimal margin. Usually, several fields are used, with precise dosimetric and positioning verification. SBRT alone is used in patients with early clinical stage, without mediastinal lymphnodes involvement, who cannot undergo surgery due comorbidities, poor clinical performance or to those who refuse surgery. Patients with centrally localized lesions are not the best candidates to SBRT due to tumor's proximity to critical structures [11, 12] .
The other patients, who do not fulfill those criteria, can be occasionally qualified to SBRT [13, 14, 15] . It, however, entails use of lower dose fractions, in order to minimize the risk of complications.
This study presents the analysis of treatment outcome in patients with NSCLC treated with SBRT as a sole curative treatment with curative intent, as stereotactic boost after fractionated radiotherapy or as a salvage treatment, after conventional radiotherapy. Table 1) . Eighty percent (49/61) of patients were males. Eighteen patients (30%) received chemotherapy in the course of their treatment. The age ranged between 48 and 89 years with a median of 69 years. The histopatological diagnosis was provided in 93% (57/61) of patients; it was squamous cell carcinoma in 57%, adenocarcinoma in 15%, and non-small cell carcinoma in 21%, one patient had NOS lung cancer and in three patients the diagnosis was based on imaging only. The follow up ranged from 2 months to 4 years with a median of 16 months.
Patients and Methods

Patients
Selection criteria and fractionation schemes. SBRT as a sole radical treatment was most commonly prescribed in patients with stage I non-small cell lung cancer (NSCLC), in good performance status (Zubrod 0-2), who did not have surgery due to comorbidities or who refused surgical treatment. Tumor diameters were less than 5cm in its greatest dimension, and tumor had to be located more than 2cm outside the proximal part of bronchial tree. Lymphnodes could not be involved. It was assumed that nodes measuring less than 1cm in short axis were not suspected of metastasis. Otherwise, radiologically suspected lymphnodes had to be verified by EBUS or PET. The typical dose delivered in that group of patients was 54Gy-60Gy in three fractions of 18 -20Gy. The fractionation used in a subgroup treated with SBRT alone is presented in Table  2 . Patients with larger or centrally located tumor treated with SBRT usually received smaller doses per fraction. There were two patients with small tumors treated with one single fraction of 24Gy. Altogether, there were 30 patients treated with SBRT as a sole treatment. SBRT as a form of boost was used in 11 patients. It was administered either to primary tumor before CRT (5 patients) or to residual tumor after CRT (6 patients). The SBRT doses in that group of patients were 10Gy-32Gy in one or two fractions (Table 3 ).
The last group of patients had SBRT due to local failure after conventional radiotherapy. There were 20 patients treated in such way and the SBRT doses in those patients ranged from 10-39Gy given in one to three fractions. In all of these patients the LQED from CRT was considered 0 Gy for tumor, because repopulation resulting in recurrence apparently outweighed the effect of dose accumulation from CRT (Table 3) .
Irradiation technique. During simulation and treatment patients were immobilized in vacuum-fitted stereotactic body mattress, in supine position. To improve the reproducibility, patients setup was marked on the mattress and corresponding point at patients skin. Breathing motion was assessed by sequential CT scans, which should cover at least one complete respiratory cycle. The sensors fixed with a belt to patients upper abdomen allowed to register the respiratory phase. In the case when tumor breathing motion was smaller than 5mm the treatment was delivered with free quiet breathing. Otherwise, respiratory gating technique was used, described in other study from our institution [16] . The respiratory phase with smallest tumor movement was chosen -usually the last 20-30% of expiratory motion. The GTV was delineated only on CT scans corresponding to the chosen phase of respiratory cycle. The CTV was generated by adding a 5mm margin to GTV, whereas PTV was individual depending on tumor motion in the gated portion of the respiratory phase. During simulation, metaplex markers were placed on the upper abdomen. Their respiratory motion was recorded by infrared videocamera. The signal detected by the videocamera initiated radiation only during the chosen respiratory phase. The dose was prescribed to the 95% isodose covering 100% of the PTV.
Tumor response and local control assessment. Local failure was defined as the progression of cancer within irradiated volume (SBRT), distant failure as the recurrence elsewhere. It was assed with the use of CT scans or chest radiograph performed first 3 months after treatment and 6 months thereafter. Subsequent results allowed to assess local control. PET was used to discriminate between late progression and radiation fibrosis, whenever required.
Toxicity of treatment. Toxicity of SBRT was assessed retrospectively and based on symptoms reported by patients during treatment and follow up and scored according to RTOG Criteria. Symptoms that occurred six months or more after treatment were scored as late toxicity. Symptoms reported before treatment or which occurred due to progression were not considered as treatment toxicity.
Statistical analysis. Doses of each fraction of SBRT were converted into Linear Quadratic Equivalent Dose at 2Gy per fraction (LQED2) according to the equation: df*[(df+ α/β)/(2Gy+ α/β)] [16] . The α/β ratio for tumor was assumed to be 10Gy, 2Gy is the fraction dose in conventional radiotherapy and df is dose per fraction in SBRT. The total dose delivered during the entire course of SBRT ( LQED2-SBRT) was calculated as the sum of all its fractions. This allowed comparison of doses delivered in various fractions. The same equation was used to convert doses of fractionated radiotherapy when fraction doses other than 2Gy were used, and the result was called LQED2-CRT (Conventional Radiotherapy). The total dose that patients received was the sum of SBRT and conventional radiation called total-LQED2.
Since the schemes differed not only in the total dose delivered but also in the time intervals between the fractions of SBRT and interval SBRT -conventional radiation, the effect of cell repopulation was accounted. Therefore, the dose equivalent of tumor repopulation required to compensate for newly formed clonogens was subtracted from the total-LQED2. The resulting dose was called total-LQED2-r. It was assumed that 
28-150 (126) LQED2-r -sum of doses of conventional radiotherapy and SBRT with consideration of repopulation Overall treatment time -time interval between start of CRT and end of SBRT Table 3 . Dose-fractionation used in 31 patients treated both with CRT and SBRT according to the total dose from CRT. cancer cell repopulation starts 30 days after the onset of radiotherapy and dose required to compensate this phenomenon is 0,5 Gy per day [17, 18] . Therefore, 0,5 Gy was subtracted from the total LQED2 for each day of treatment over 30 days. It applied to both intervals between SBRT and conventional radiotherapy as well as duration of SBRT.
The whole group was divided into three subgroups according to the biologically-equivalent doses received (total-LQED-r): more than 110Gy (14 patients), between 60Gy and 110Gy (17 patients), less than 60Gy (30 patients). Recurrence-free survival curves were plotted using Kaplan-Meier method. Univariate and multivariate analysis were performed using Cox analysis.
Results
Local control. Two year local control in the group of patients who received more than 110Gy was 81%. It was 51% in patients who received between 60 and 110Gy and 33% in those who received less than 60Gy (Fig.1) . The differences in local con- (Table 4) . On multivariate Cox analysis, however, only nodal status turned out statistically significant (p=0,01). There was no influence of age, gender, tumor volume or histology. Fig. 2 presents the metastasis free survival according to total-LQED2-r.
Treatment toxicity. In general, 29,5% (18/61) of patients reported symptoms which may have been caused by SBRT. Ten (16%) of those patients complained of dyspnea or cough of grade 1-2 in RTOG scale (Table 5 ). There was 1 case of pleural effusion with dyspnea and 1 case of hemoptysis, which resolved with time. Four patients complained of chest wall pain, and in two patients skin pigmentation changes were observed. In seven patients symptoms persisted more than six months. Grade 3-4 toxicity was not observed.
Discussion
In general, the present analysis supports the studies that demonstrate high effectiveness of SBRT in the treatment of NSCLC. It shows that dose escalation without undue treatment time extension, can lead to substantial improvement in local control. This conclusion is supported by other authors [9, 19, 20] . The present analysis indicates that patients with early stage NSCLC, treated by SBRT should receive LQED2 doses higher than 110Gy. It should be emphasized that satisfactory outcomes achieved by SBRT as a sole treatment are considerably better than those after conventional fractionation [21] . The published results indicate that local control after sole SBRT ranges from 70% to 100% [9, 22] . The present study demonstrates that local control in the group of patients who received doses higher than 110Gy is within this range. Local control in patients who received lower doses is, however, not satisfactory. Mostly the patients treated due to recurrence of advanced tumors or treated for residual tumor were in this group. Moreover, due to previous radiotherapy many patients could not receive doses rendering high probability of local control. In such cases SBRT had, actually, palliative effect.
We note that all patients treated with SBRT in present series were not considered as candidates for surgery. The comparison of standard surgery and SBRT in operable patients with early stage NSCLC is a subject of on-going studies and must not be considered at present as standard of care. Likewise, surgical resection of recurrent NSCLC should be preferred to SBRT if clinically feasible.
The present results suggest that tolerance of SBRT was acceptable. Although substantial part of the group (30/61) were patients previously treated with conventional radiotherapy, no excessive increase in the treatment toxicity was recorded.
The conclusions from the present study have limitations typical for the retrospective research. The total study sample is relatively small, particularly considering its clinical heterogeneity. Nevertheless, its general outcome indicates that SBRT provides new opportunities to increase local control or delay disease progression in patients with limited therapeutic options.
